Trademark Overview
On Friday, March 8, 2024, a trademark application was filed for ACELLYTRON THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the ACELLYTRON THERAPEUTICS trademark a serial number of 79406657. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, October 30, 2024. This trademark is owned by Wuxi Biologics (Shanghai) Co., Ltd.. The ACELLYTRON THERAPEUTICS trademark is filed in the Advertising, Business and Retail Services, Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Chemico-pharmaceutical preparations; biochemical medicines; vaccine preparations; influenza vaccine; chemotherapeutics; stem cells for medical purposes; medicines for human purposes; drugs for medical purposes; pharmaceutical preparations; drugs for cancer; medical preparation for treating diseases and disorders related to the immune system; biological agent for treating cancer; pharmaceutical products for the prevention and treatment of cancer; living cells for medical use; medical cell inhibitor; reagents for medical purposes; anticancer agent; diagnostic reagents for medical purposes; tumor suppressor; medical cell; dietetic substances adapted for medical use; biological preparations for veterinary purposes.
Online advertising on a computer network; advertising; publicity; dissemination of advertising and advertising matter（flyers, prospectuses, brochures, leaflets and samples); providing commercial information and advice for consumers in the choice of products and services; organization of exhibitions and trade fairs for commercial or advertising purposes; import-export agency services; marketing; sponsorship search; retail services for pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies.
Preparation of prescriptions by pharmacists; stem cell therapy services; medical clinic services; provide medical information (Term considered linguistically incorrect by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); DNA screening (for medical purposes); medical analysis services for the diagnosis of cancer; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical screening; health care; medical assistance.
Research and development of new products for others; technological research; chemical analysis; research and analysis of biochemistry; research and development of pharmaceuticals; medical research service; research and development of antibodies; stem cell research services; medical research; clinical trials; biological research; computer programming of medical aspects (Term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations).
